12:00 AM
 | 
Dec 24, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Anti-NKG2D: Development discontinued

Novo Nordisk discontinued development of anti-NKG2D to treat CD after an interim futility analysis of 74 patients in a double-blind, placebo-controlled Phase IIa trial showed that the compound did not...

Read the full 127 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >